BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/23/2025 6:25:21 AM | Browse: 4 | Download: 13
 |
Received |
|
2025-10-27 03:28 |
|
Peer-Review Started |
|
2025-10-27 03:28 |
|
First Decision by Editorial Office Director |
|
2025-10-30 08:52 |
|
Return for Revision |
|
2025-10-30 08:52 |
|
Revised |
|
2025-10-30 14:51 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-20 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-20 05:53 |
|
Articles in Press |
|
2025-11-20 05:53 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-09 11:04 |
|
Publish the Manuscript Online |
|
2025-12-23 06:25 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abdellatif Bouayad |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdellatif Bouayad, Associate Professor, MD, Department of Immunology, Faculty of Medicine and Pharmacy Oujda, Mohammed First University, Mohammed V Avenue, Oujda-Angad 60049, Oriental, Morocco. abdellatifbouayad@hotmail.fr |
| Key Words |
Antitumor immunity; Therapy; Prognosis; Cancer; Ectonucleoside triphosphate diphosphohydrolase 6 |
| Core Tip |
Ectonucleoside triphosphate diphosphohydrolase 6 (ENTPD6) has dual effects on cancer development and progression, influencing immune surveillance and immune evasion through tumor microenvironment modulation. It serves as a promising novel molecular biomarker for prognosis and for predicting cancer therapy responses. Furthermore, ENTPD6-derived neopeptide vaccines, as well as adoptive T-cell transfer using T cells engineered with T-cell receptors targeting ENTPD6, may constitute promising strategies in cancer immunotherapy. |
| Publish Date |
2025-12-23 06:25 |
| Citation |
Bouayad A. Ectonucleoside triphosphate diphosphohydrolase 6: A double-edged sword in cancer prognosis and therapy. World J Clin Oncol 2025; 16(12): 115789 |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i12/115789.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i12.115789 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
